Pds Biotechnology CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
PDS Biotechnology Corporation has issued its proxy statement for the 2026 Annual Meeting, seeking approval for director elections, an increase in authorized common stock, and executive compensation.
NASDAQ
DEFR14A: PDS Biotechnology Revises Equity Overhang and Burn Rate Projections Ahead of Annual Meeting
PDS Biotechnology amends its proxy statement to revise the description of its total equity overhang and historical and projected burn rate in connection with Proposal 2, concerning the amendment of the 2014 Equity Incentive Plan.
NASDAQ
PDS Biotechnology amends its proxy statement to revise details regarding equity overhang and burn rate related to the proposed amendment of its 2014 Equity Incentive Plan.
NASDAQ
PDS Biotechnology Corporation has filed a definitive proxy statement with the SEC.
NASDAQ
DEF: PDS Biotech Seeks Stockholder Approval for Equity Incentive Plan Amendment at 2025 Annual Meeting
PDS Biotechnology Corporation is seeking stockholder approval to amend its 2014 Equity Incentive Plan to increase the number of shares available for issuance at the Annual Meeting of Stockholders to be held on June 11, 2025.
NASDAQ
PDS Biotechnology Corporation has filed a definitive proxy statement with the SEC.
NASDAQ
PDS Biotechnology Corporation is holding its Annual Meeting of Stockholders on June 24, 2024, to elect directors, approve an increase in authorized common stock, ratify the selection of KPMG LLP as its auditor, and conduct an advisory vote on executive compensation.